

# ADVANCES IN RECURRENT / METASTATIC NASOPHARYNGEAL CARCINOMA: IMMUNOTHERAPY AND BIOMARKERS

## Clinical Resources

### Guidelines

Pfister DG, Spencer S, Adkins D, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Head and Neck Cancers. Version 3.2024. Published online February 29, 2024. Accessed April 28, 2024.

[https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf)

Schneider BJ, Naidoo J, Santomaso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. *J Clin Oncol*. Published online November 1, 2021. doi:10.1200/JCO.21.01440

Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Management of Immunotherapy-Related Toxicities. Version 1.2024. Published online December 7, 2023. Accessed February 12, 2024. [https://www.nccn.org/professionals/physician\\_gls/pdf/immunotherapy.pdf](https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf)

### Key Clinical Trials

Mai HQ, Chen QY, Chen D, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: The JUPITER-02 randomized clinical trial. *JAMA*. 2023;330(20):1961-1970. doi:10.1001/jama.2023.20181

Wang FH, Wei XL, Feng J, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase clinical trial (POLARIS-02). *J Clin Oncol*. 2021;39(7):704-712. doi:10.1200/JCO.20.02712

Yang Y, Pan J, Wang H, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). *Cancer Cell*. 2023;41(6):1061-1072.e4. doi:10.1016/j.ccell.2023.04.014

Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2021;22(8):1162-1174. doi:10.1016/S1470-2045(21)00302-8


### Pertinent Review Articles

Bossi P, Gurizzan C, Chan A. Immunotherapy for nasopharyngeal carcinoma: The earlier the better. *JAMA*. 2023;330(20):1954-1955. doi:10.1001/jama.2023.22465

Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, et al. Recurrent/metastatic nasopharyngeal carcinoma treatment from present to future: Where are we and where are we heading? *Curr Treat Options Oncol*. 2023;24(9):1138-1166. doi:10.1007/s11864-023-01101-3

National Cancer Institute. Nasopharyngeal Carcinoma Treatment (PDQ®) - NCI. July 26, 2024. Accessed August 12, 2024. <https://www.cancer.gov/types/head-and-neck/hp/adult/nasopharyngeal-treatment-pdq>

Saba NF. Immunotherapeutics in nasopharyngeal carcinoma: a relentless CONTINUUM of success. *The Lancet*. 2024;403(10445):2667-2669. doi:10.1016/S0140-6736(24)00810-9



**Patient Education**

American Association for Cancer Research: <https://www.aacr.org/patients-caregivers/cancer/nasopharyngeal-cancer/>

American Cancer Society: <https://www.cancer.org/cancer/types/nasopharyngeal-cancer/about/what-is-nasopharyngeal-cancer.html>

National Cancer Institute: <https://www.cancer.gov/types/head-and-neck/patient/adult/nasopharyngeal-treatment-pdq>